These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18477894)

  • 1. Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma.
    Vucetić B; Rogan SA; Hrabac P; Hudorović N; Cupić H; Lukinac L; Ledinsky M; Matejcić A; Lovricević I; Zekan M
    Melanoma Res; 2008 Jun; 18(3):201-7. PubMed ID: 18477894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
    Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U
    J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
    Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
    Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
    Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
    Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
    Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
    Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MIA, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
    Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum markers for melanoma].
    Ugurel S
    Hautarzt; 2005 Feb; 56(2):173-84; 185-6. PubMed ID: 15657726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma.
    Hochberg M; Lotem M; Gimon Z; Shiloni E; Enk CD
    Br J Dermatol; 2002 Feb; 146(2):244-9. PubMed ID: 11903234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Melanoma inhibitory activity (MIA). Evaluation of a new tumor-associated antigen as a serum marker for uveal melanomas].
    Schaller UC; Mueller AJ; Bosserhoff AK; Haraida S; Löhrs U; Buettner R; Kampik A
    Ophthalmologe; 2000 Jun; 97(6):429-32. PubMed ID: 10916387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population.
    Li C; Liu J; Jiang L; Xu J; Ren A; Lin Y; Yao G
    Medicine (Baltimore); 2021 Feb; 100(8):e24840. PubMed ID: 33663104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma.
    Meral R; Duranyildiz D; Tas F; Camlica H; Yasasever V; Kurul S; Dalay N
    Melanoma Res; 2001 Dec; 11(6):627-32. PubMed ID: 11725209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes.
    Porter GA; Abdalla J; Lu M; Smith S; Montgomery D; Grimm E; Ross MI; Mansfield PF; Gershenwald JE; Lee JE
    Ann Surg Oncol; 2001 Mar; 8(2):116-22. PubMed ID: 11258775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
    Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
    J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi.
    Saab J; Santos-Zabala ML; Loda M; Stack EC; Hollmann TJ
    Am J Dermatopathol; 2018 Apr; 40(4):259-264. PubMed ID: 28654463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes.
    Mentrikoski MJ; Ma L; Pryor JG; McMahon LA; Yang Q; Spaulding BO; Scott GA; Wang HL; Xu H
    Mod Pathol; 2009 Dec; 22(12):1582-7. PubMed ID: 19734845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
    Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
    Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel node identification by scintigraphic methods in cutaneous melanoma.
    Dias Moreira R; Altino de Almeida S; Maliska Guimarães CM; Resende JF; Gutfilen B; Barbosa da Fonseca LM
    J Exp Clin Cancer Res; 2005 Jun; 24(2):181-5. PubMed ID: 16110749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of multiple serum markers in advanced melanoma.
    Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A
    Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients.
    Damude S; Hoekstra HJ; Bastiaannet E; Muller Kobold AC; Kruijff S; Wevers KP
    Eur J Surg Oncol; 2016 Apr; 42(4):545-51. PubMed ID: 26831006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.